Phase 1/2Completed
Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease (STAMINA)
Senolytics To Alleviate Mobility Issues and Neurological Impairment in Aging
- Sponsor
- Lewis Lipsitz (Academic or other)
- Enrolment
- 15 enrolled
- Conditions
- Aging
- Interventions
- Dasatinib; Quercetin
- Ages
- older adults
- Registry
- NCT05422885
From the registry
The purpose of this pilot study is to demonstrate the safety and feasibility of administering intermittent doses of Dasatinib and Quercetin (D+Q) in older adults at risk of Alzheimer's disease (AD). The study will evaluate whether giving D+Q may improve cerebral blood flow regulation, mobility, and cognition in older adults, and thus may prevent progression to Alzheimer's disease.
Primary outcomes
- Neurovascular Coupling
- Executive Function
- Gait Speed
- Montreal Cognitive Assessment (MoCA) Score